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study of 100 adult asthmatics. RESULTS: The table re-
ports outcomes over a 10-year period. Results were driven
by the impact of ICS on quality of life, rather than on
mortality. Findings were stable over most input data
ranges. However, at efficacy levels below 3% and toxic-
ity rates greater than 2.9%, the cost-effectiveness esti-
mate exceeded $100,000/QALY. CONCLUSION: Results
suggest that inhaled steroids deliver good comparative
value in mild-to-moderate adult asthma. More research is
needed, however, on the impact of ICS toxicity on patient
preferences.
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JOINT COUNTS IN PATIENTS WITH NEW 
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PHYSICIAN ASSESSMENT
Kim SS, Drabinski AM, Williams GR, Formica CA
Knoll Pharmaceutical Company, Mount Olive, NJ, USA
BACKGROUND: Both physician-assessed and patient
self-reported joint counts have been used in the assess-
ment of disease activity in rheumatoid arthritis. The ob-
jective of this study was to compare patient vs. physician
reported joint counts in patients with new onset RA.
METHODS: Baseline data was analyzed from the Study
of New Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM),
a five-year prospective, longitudinal, inception cohort
study to document long-term functional, clinical, and hu-
manistic outcomes and patterns of treatment in patients
with new onset RA. Baseline data collection consisted of
physician and patient surveys. Physicians assessed swol-
len (SJ) and tender/painful joints (TJ) while patients re-
ported painful joint (PJ). Physician’s SJ and TJ consisted
of examination in 64 and 66 joints, respectively. Patient’s
PJ was assessed in 16 joint areas with use of a manne-
quin. The Pearson product moment correlation coeffi-
cient was calculated for SJ, TJ, and PJ counts. RESULTS:
One hundred and seven patients completed the baseline
survey. Mean age of the sample was 55  15 years; 79%
were female; 80% were Caucasian. Mean joint counts were
12.6 (SE  0.9) SJ, 14.0 (SE  1.3) TJ, and 6.6 (SE 
0.4) PJ. Patient-reported PJ correlated with physician-
Strategy Cost QALY $QALY
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ICS in mild disease $7,616 6.93 dominated
ICS in mild/mod. disease $8,392 7.00 $15,000
reported SJ (r  0.22, p  0.023) and TJ (r  0.55, p 
0.001). CONCLUSION: Higher correlation was observed
between PJ and TJ compared to SJ. Patient, self-reported
joint counts may be a useful surrogate of joint activity in
the absence of physician assessment. However, caution
should be taken given that the accuracy of patient, self-
reported joint counts still needs further evaluation. Five-
year follow-up of this population will provide further in-
sight on the sensitivity to change for both patient and
physician reported joint counts as it relates to disease ac-
tivity.
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Osteoporosis affects approximately 24 million Americans
and accounts for an estimated annual direct medical costs
of over $13.8 billion. An economic analysis that evalu-
ates the effectiveness of osteoporosis medications for pre-
vention of bone fractures in a naturalistic setting has not
been formally conducted. OBJECTIVES: To compare
differences among four therapeutic alternatives [estrogen
replacement therapy (ERT), raloxifene, nasal calcitonin,
and alendronate] with respect to health care costs (phar-
macy, medical, and total), and time to fracture. METH-
ODS: Retrospective pharmacy and medical claims data
from a large managed care organization were analyzed.
Patients were included if they were diagnosed with os-
teoporosis and newly initiated on medication between
1/1/98–12/31/98. All patients were followed for exactly 1
year. Cost data was log-transformed to correct for skew-
ness. ANCOVA was conducted to compare total health
care costs; Cox Proportional Hazard Model was per-
formed to compare the risk of fracture. Total health care
costs was defined as all osteoporosis-related services cov-
ered. RESULTS: There were 12,757 female patients iden-
tified for the analysis and the average age was 70(S.D. 
10). A total of 1,721(13.5%) patients had a fracture after
initiation of drug therapy. After adjusting for age, prior
medication costs, prior fracture event, and comorbidities,
adjusted means (95%CI) of log-transformed total health
care costs was lowest for ERT 5.87(5.84–5.90), com-
pared to raloxifene 6.32(6.19–6.46), alendronate
6.55(6.51–6.59) and calcitonin 7.20(6.61–7.80). Com-
pared to calcitonin, the adjusted hazard ratios (95%CI)
for a fracture were 0.174(0.078–0.39) for ERT,
0.175(0.078–0.39) for alendronate, and 0.160(0.068–
0.377) for raloxifene. CONCLUSIONS: In this popula-
tion, ERT was associated with statistically significant
lower total health care costs compared to raloxifene, al-
endronate, and calcitonin. Raloxifene was associated
with statistically significant lower total health care costs
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compared to calcitonin and alendronate. Furthermore,
hazard ratios showed that patients taking ERT, ralox-
ifene, or alendronate were approximately 83% less likely
to experience fracture at any point in time compared to
calcitonin.
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BACKGROUND: The UK has more than 19 million peo-
ple aged over 50, including about 9.4 million aged over
65. Demographic changes will lead to increases in the
over-50 population of 10% and 25% by 2010 and 2020,
respectively. There are already 3 million UK residents
with osteoporosis, but the prevalence of osteoporosis in-
creases with age, and the public health impact of os-
teoporosis will increase substantially over the next 20
years. OBJECTIVE: To predict fracture numbers and
corresponding costs for men and women aged 50–99
years in the UK for the years 2000 to 2020. METHODS:
A Markov model was designed to simulate the natural
history of osteoporosis within the UK population. Inputs
to the model included age/sex specific fracture incidence
rates, published unit costs for different fracture types
(hip, vertebral, forearm/wrist, other), age/sex specific
mortality rates, and age/sex specific population totals.
Total fracture numbers were adjusted using published
site-specific attribution figures to identify the number
that were a consequence of osteoporosis. Iteration tech-
niques were employed across ages 50–99 in men and
women, to generate the distribution of prevalence-based
estimates of fractures and costs for the base year 2000.
Osteoporosis costs and fracture numbers were then pro-
jected into future years by applying growth rates in age/
sex specific population totals to these year 2000 esti-
mates. RESULTS: In 2000 there were 190,000 os-
teoporosis-related fractures at a cost of £1.8 billion. Men
accounted for 32,000 fractures and £330 million. By
2020, annual osteoporotic fracture numbers increased by
over 21% to 230,000, with costs growing by 20% to
over £2.1 billion. Cumulative totals for 2000–2010 were
2.2 million fractures and £20.3 billion. CONCLUSIONS:
Osteoporotic fractures will have substantial and increas-
ing impacts on UK health services unless highly effective
preventative interventions achieve widespread use.
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OBJECTIVE: While Cox 2 inhibitors have a theoretical
advantage over other nonsteroidal anti-inflammatory
drugs (NSAIDS) by reducing gastrointestinal (GI) side ef-
fects, not all individuals are at increased risk of GI com-
plications and therefore may benefit equally from non-
Cox 2 specific NSAIDS. This study determined the use of
Cox 2 inhibitors by subjects with no identifiable GI risk.
The cost of this “inappropriate use” was estimated.
METHODS: This was a longitudinal claims data analysis
using 1999 medical, pharmacy and enrollment data from
a large national health plan. Subjects were identified as
either Cox 2 users (n  23,190) or other NSAID users
(n  192,079) from pharmacy claims, and total NSAID
costs were calculated for a six-month period. RESULTS:
Cox 2 users were more likely to have a GI risk factor,
(prior GI events, age over 60 years, chronic NSAID use of
two or more prescriptions in the six months prior to the
first Cox 2 claim, and prior corticosteroid use) compared
to other NSAID users. Because individuals with arthritis
may require on-going NSAID use, a diagnosis of arthritis
(OA or RA) was also considered a risk factor for GI com-
plications. Having an arthritis diagnosis was more likely
among Cox 2 users compared to other NSAID users
(44.1% and 13.0% respectively). Twenty-six percent of
Cox 2 users had neither a discernable GI risk nor an ar-
thritis diagnosis. An unadjusted cost comparison between
Cox 2 subjects with no GI risk and no arthritis and simi-
lar other NSAID subjects found a significant mean differ-
ence of $131 per person in NSAID costs for six months.
CONCLUSIONS: Despite health plan policies to manage
the use of Cox 2 inhibitors, a quarter of Cox 2 users ap-
peared to be inappropriate. The total health system cost
of this potentially inappropriate use was $775,000 for six
months.
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OBJECTIVES: Quality of life is a key parameter in de-
scribing the health status patients of rheumatoid arthritis.
Construct validity of a generic (EQ-5D) and a disease
specific (RAQoL) quality of life instrument was tested
with the intention of further use in clinical and health
economic trials and burden of disease studies in Hun-
gary. METHODS: RAQoL and EQ-5D have been re-
cently adapted into Hungarian. Authors analysed the de-
mographic and QoL data from a cross-sectional postal
survey of patient with rheumatoid arthritis. The conver-
gent validity of EQ-5D, RAQoL scores has been com-
pared to functional measurement scores from the Health
Assessment Questioner (HAQ). Pearson correlation coef-
